Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • haematological cancer

    - PMLiVE

    MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

    More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

    - PMLiVE

    Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer

    More than 72,680 new cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    Merck shares promising phase 3 results for Keytruda in ovarian cancer

    Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

    Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

    - PMLiVE

    Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours

    The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes

    - PMLiVE

    Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

    - PMLiVE

    BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

    Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

    - PMLiVE

    BMS receives FDA approval for immunotherapy combination in liver cancer

    Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

    - PMLiVE

    BMS granted FDA approval for immunotherapy combination in colorectal cancer

    More than 154,000 cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer

    Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection

    - PMLiVE

    BMS granted EC approval for immunotherapy combination in liver cancer

    More than 866,100 cases of the disease were diagnosed globally in 2022

    - PMLiVE

    BMS shares overall survival results for Opdivo in phase 3 lung cancer trial

    More than 200,000 people are diagnosed with lung cancer in the US every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links